Return to homepagePandemic Pact

COVMAB. Discovery of neutralizing monoclonal antibodies in SARS-CoV-2 infection.

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    University of São Paulo

  • Principal Investigator

    N/A

  • Research Location

    Brazil

  • Lead Research Institution

    Hospital das Clínicas

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

In response to this ongoing public health emergency, the development of prophylactic and therapeutic approaches is necessary, as strategies to contain the spread of SARS-CoV2 seem not to be fully effective and the management of COVID-19 is based on supportive care only. Considering the relevance of neutralizing antibodies (Abs) in preventing viral replication, the therapeutic use of these molecules may represent a promising strategy for combating, preventing and treating SARS-CoV-2 infections. Thus, the aim of this study is to identify and characterize monoclonal Abs neutralizing against SARS-CoV-2 derived from B cells obtained from patients with clinical and laboratory diagnosis of COVID-19, during the acute (plasmoblast) and convalescent (memory B cell) phases of infection.